PT-150 is under clinical development by Palisades Therapeutics and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PT-150’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PT-150 overview

PT-150 (ORG-34517) is under development for the treatment of CNS addiction of opioid, nicotine (smoking cessation) and alcohol dependence, pancreatic cancer, glioblastoma, drug-resistant prostate cancer, ovarian cancer, triple-negative breast cancer, Covid-19, Parkinson's disease, Alzheimer's disease and depression, fatigue, memory dysfunction, brain fog associated with long haul COVID syndrome, middle east respiratory syndrome (MERS) and influenza A. It is administered through oral route. The drug candidate acts by targeting glucocorticoid receptor (GR) translocation, corticosterone-induced GR translocation and androgen receptor (AR). The drug candidate in combination with chemo therapeutics is used as a chemo sensitizer.

For a complete picture of PT-150’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.